Objective To describe the epidemiological profile and the survival rate of patients with acute myeloid leukemia (AML) in a state reference pediatric hospital. Method Clinical鈥揺pidemiological, observational, retrospective, descriptive study. The study included new cases of patients with AML, diagnosed ...
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368–77. Article CAS Google Scholar Traulsen A, Lenaerts T, Pacheco JM, Dingli D. On the dynamics of neutral ...
et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501–1510 (2012). 31. Abbott, L. H. & Michor, F. Mathematical models of targeted cancer therapy. Br. J. Cancer 95, 1136–1141 (2006). 32. Glauche, I., Horn,...
although no survival advantage was observed. No randomized studies have compared imatinib to 2G-TKIs in pediatric patients, but molecular response rates with 2G-TKIs seem to be comparable to those seen adults. In adults, it remains a matter of debate which TKI should be used for first...
Flow Diagram of the Study Selection Process View LargeDownload ALL indicates acute lymphoblastic leukemia; MRD, measurable residual disease. Figure 2. Estimated Survival Curves, Stratified by Measurable Residual Disease (MRD) Status View LargeDownload Overall survival (OS) (A) and disease-free survival...
The advent of the tyrosine kinase inhibitors has markedly changed the prognostic outlook for patients with Ph+ and/or BCR-ABL1+ chronic myeloid leukemia (CML). This study was designed to assess the overall survival (OS) of Nigerian patients with CML receiving imatinib therapy and to identify th...
摘要: A 55-year old woman was diagnosed as having chronic myeloid leukemia in 1961. After 9 years with stable white blood cells, progression of the disease was noted (white cells up to 180×109/l; splenomega关键词: Chronic myeloid leukemia Long survival Miliary tuberculosis ...
The OMU researchers' study showed markedly better survival rates after one year for the venetoclax combination therapy group than a control group of 61 patients, at 66.7% to 27.3%. They also showed in the immunological study that the alterations of immune...
A study published in the journal Hematological Oncology analyzed the outcomes of 263 patients with acute myeloid leukemia (AML) who were treated with hypomethylating agents (HMAs) and venetoclax. The study aimed to identify simple baseline predictors of overall survival (OS) in this patien...
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhi